Loading
NASDAQHealthcareBiotechnology
Latest quote
$25.67
−$1.01 · -3.79%
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Previous close
$25.67
−$1.01 · -3.79%
After-hours
$25.69
+$0.02 · +0.08%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Day range
Current $25.67
52-week range
Current $25.67
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
62
Bullish
Risk
52
Elevated Risk
Momentum
55
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Day range
Current $25.67
52-week range
Current $25.67
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 3.9M USD | — | — | — | — |
| Gross profit | −3.9M USD | — | — | — | — |
| Research and development | 225.26M USD | 108.81M USD | 70.1M USD | 36.19M USD | 29.11M USD |
| Selling, general, and administrative | 61.55M USD | 49.41M USD | 32.67M USD | 16.37M USD | 8.59M USD |
| Operating expenses | 283.67M USD | 158.23M USD | 102.78M USD | 52.56M USD | 37.7M USD |
| Interest income | 35.97M USD | 36.03M USD | 13.38M USD | 1.26M USD | 122 USD |
| Interest expense | — | — | 13.39M USD | — | 122.16K USD |
| Depreciation and amortization | 1.33M USD | 992K USD | 295K USD | 277K USD | 72K USD |
| Operating income | −287.57M USD | −158.23M USD | −102.78M USD | −52.56M USD | −37.7M USD |
| Net income | −141.2M USD | −122.53M USD | −89.62M USD | −51.32M USD | −40.01M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$90.50
252.55% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB12.46M0.12%10.41B USD0.44%$200.48-1.41%
American Century Focused Dynamic Growth ETFFDG3.32M0.81%438.84M USD0.45%$136.55-1.28%
ALPS Medical Breakthroughs ETFSBIO2.42M1.28%188.26M USD0.50%$53.945-0.34%
Fidelity Fundamental Small-Mid Cap ETFFFSM2.24M0.14%1.44B USD0.43%$33.92-0.24%
State Street SPDR Portfolio Emerging Markets ETFSPEM2.24M0.01%17.75B USD0.07%$51.53-1.28%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM1.17M2.13%56.4M USD0.59%$29.2897-2.66%
American Century Mid Cap Growth Impact ETFMID960.21K0.95%107.13M USD0.45%$71.6101-0.58%
TrueShares Technology, AI and Deep Learning ETFLRNZ896.45K2.00%44.87M USD0.68%$67.60-2.11%iShares Biotechnology ETFIBBAmerican Century Focused Dynamic Growth ETFFDGALPS Medical Breakthroughs ETFSBIOFidelity Fundamental Small-Mid Cap ETFFFSMState Street SPDR Portfolio Emerging Markets ETFSPEMRoundhill Investments - GLP-1 & Weight Loss ETFOZEMAmerican Century Mid Cap Growth Impact ETFMIDTrueShares Technology, AI and Deep Learning ETFLRNZAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
